Search results
Added:
6 months ago
HsCRP in ASCVD
Added:
7 months ago
Article
Added:
1 day ago
AHA Scientific Sessions 2025 - Dr Michelle O'Donoghue (Brigham and Women's Hospital, US) joins us to discuss the evolving understanding of the causal relationship between elevated lipoprotein(a) and atherosclerotic cardiovascular disease, and what this means for risk stratification and management strategies in clinical practice.Dr O'Donoghue begins by highlighting the importance for clinicians to…
View more
Added:
1 year ago
ACC.24 — Dr Brian Bergmark (Brigham and Women's Hospital, Harvard Medical School, US) joins us in this interview to discuss the findings of a study into olezarsen, previously known as AKCEA-APOCIII-LRx, in patients with hypertriglyceridemia and atherosclerotic cardiovascular disease (ASCVD), with or without severe hypertriglyceridemia (NCT05355402).This multicenter, randomized, double-blind study…
View more
Added:
2 years ago
ESC 23 — Dr Michelle O'Donoghue (Brigham and Women's Hospital, US) outlines a trial update from OCEAN(a)-Dose Extension trial (NCT05581303) in this succinct interview.
OCEAN(a)-DOSE (Amgen) was a dose-finding study aiming to evaluate a siRNA, olpasiran, and its effect on risk for coronary heart disease death, myocardial infarction or urgent coronary revascularization when administered…
View more
Added:
2 months ago
ESC Congress 2025 - The SEMA-VR CardioLink-15 trial revealed that semaglutide may enhance endogenous progenitor cell-mediated vasculogenic repair processes.Dr Subodh Verma (University of Toronto, Toronto, CA) joins us to discuss the findings from the SEMA-VR CardioLink-15 trial. The study compared usual care with semaglutide, GLP-1RA for six months in 46 patients with either type 2 diabetes…
View more
Added:
11 months ago
AHA Conference 2024 - Safety and efficacy outcomes of zerlasiran (Silence Therapeutics) in adults with elevated lipoprotein(a) at high risk of atherosclerotic cardiovascular disease events (ASCVD).Dr Steven Nissen (Cleveland Clinic, US) joins us onsite at AHA Conference to discuss the findings from ALPACAR (NCT05537571).ALPACAR is a phase 2, randomized, five-arm, placebo-controlled trial…
View more
Start date:
Mar 18, 2024
End date:
Mar 21, 2024
Connecting with Expert Peers and VisionariesEngage with esteemed peers and renowned speakers in the realm of translational and population science and become a driving force for change in the realm of heart disease and stroke prevention while fostering cardiovascular health.The program boasts keynote lectures, interactive presentations focusing on population science and policy implications, a…
View more
Added:
2 months ago
ESC Congress 2025 - Pooled MACE Analysis of obicetrapib shows reductions in cardiovascular events and consistent reductions in LDL cholesterol and LP(a).Prof Stephen Nicholls (Monash Victorian Heart Institute, AU) joins us to discuss findings from a pooled major adverse cardiovascular events (MACE) analysis of obicetrapib, examining early signals of cardiovascular benefit in patients with…
View more
Added:
1 month ago
ESC Congress 2025 - Late-breaker host Dr Harriette Van Spall (McMaster University, CA) joins Prof Julie De Backer (University Hospital Ghent, BE) to discuss the newly released 2025 ESC Guidelines for the Management of Cardiovascular Disease in Pregnancy. Together, they highlight key updates, critical advances in maternal cardiovascular care, and evidence-based recommendations tailored for this…
View more